摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(4-methanesulfonyloxyphenoxy)propylbromide | 851124-38-4

中文名称
——
中文别名
——
英文名称
3-(4-methanesulfonyloxyphenoxy)propylbromide
英文别名
[4-(3-Bromopropoxy)phenyl] methanesulfonate
3-(4-methanesulfonyloxyphenoxy)propylbromide化学式
CAS
851124-38-4
化学式
C10H13BrO4S
mdl
——
分子量
309.181
InChiKey
LQDYCUUGZXHRJK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    430.7±45.0 °C(Predicted)
  • 密度:
    1.510±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    16
  • 可旋转键数:
    6
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    61
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    4-羟苯基甲磺酸盐1,3-二溴丙烷potassium carbonate 作用下, 以 丙酮 为溶剂, 反应 18.0h, 以61%的产率得到3-(4-methanesulfonyloxyphenoxy)propylbromide
    参考文献:
    名称:
    [EN] NOVEL COMPOUNDS AND THEIR USE AS ANTIDIABETIC AND HYPOLIPIDEMIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    [FR] NOUVEAUX COMPOSES ET LEUR UTILISATION EN MEDECINE, LEUR PROCEDE DE PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
    摘要:
    公开号:
    WO2005040102A3
点击查看最新优质反应信息

文献信息

  • Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them
    申请人:Debnath Bhunia
    公开号:US20070093476A1
    公开(公告)日:2007-04-26
    The present invention relates to novel compounds of formula (I) and their pharmaceutically acceptable salts, wherein ring “Ar 1 ” represents a monocyclic or polycyclic aromatic or partially saturated aromatic polycyclic, which may optionally contain up to 3 heteroatoms selected from N, S or O. The said monocyclic or polycyclic ring may be unsubstituted or have up to 4 substituents which may be identical or different; m and n independently represents an integer from 0 to 6; A represents O, S or bond; Y is selected from (CH 2 ) p′ (CH 2 ) p B(CH 2 ) q′ (CH 2 ) r B(CH 2 ) p D(CH 2 ) p′ where p, q and r each independently represents an integer from 0 to 6; B and D independently represents S, O, NR 4 or a bond, with a proviso that when B and D represents hereto atom p is not zero; R 4 represents hydrogen, alkyl, alkenyl, —S(O) 2 —R 8 or —C(O)R 8 where R 8 is alkyl, alkoxy; R 5 and R 6 independently represents hydrogen, alkyl, cycloalkyl or alkoxy; R 5 and R 6 together may form 3-8 membered cyclic ring which may optionally contains one or two hereto atoms selected from O, S or N; R 7 represents hydrogen, optionally substituted groups selected form alkyl, cycloalkyl, alkenyl or alkynyl. The present invention also relates to a process for preparation of compounds of formula (I), to pharmaceutical compositions containing compounds of formula (I) and their use in particular as antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic agents.
    本发明涉及公式(I)的新化合物及其药学上可接受的盐,其中环“Ar1”表示单环或多环芳香或部分饱和芳香多环,可选含有最多3个选自N、S或O的杂原子。所述的单环或多环环可以未取代或具有最多4个相同或不同的取代基;m和n分别表示0到6的整数;A表示O、S或键;Y选自(CH2)p′( )pB( )q′( )rB( )pD( )p′,其中p、q和r各自独立地表示0到6的整数;B和D分别表示S、O、NR4或键,条件是当B和D表示杂原子时,p不为零;R4表示氢、烷基、烯基、—S(O)2—R8或—C(O)R8,其中R8为烷基、烷氧基;R5和R6各自独立地表示氢、烷基、环烷基或烷氧基;R5和R6可以一起形成3-8成员环,该环可以选择性地包含选自O、S或N的一个或两个杂原子;R7表示氢、可选地从烷基、环烷基、烯基或炔基中选择的取代基。本发明还涉及公式(I)化合物的制备方法,含有公式(I)化合物的制药组合物以及其作为抗糖尿病、降脂、抗肥胖和降胆固醇药物的应用。
  • NOVEL COMPOUNDS AND THEIR USE AS ANTIDIABETIC AND HYPOLIPIDEMIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    申请人:Dr. Reddy's Laboratories Ltd.
    公开号:EP1680397A2
    公开(公告)日:2006-07-19
  • [EN] NOVEL COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX COMPOSES ET LEUR UTILISATION EN MEDECINE, LEUR PROCEDE DE PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
    申请人:REDDYS LAB LTD DR
    公开号:WO2005040102A2
    公开(公告)日:2005-05-06
    The present invention relates to novel compounds of formula (I) and their pharmaceutically acceptable salts, wherein ring “Ar1” represents a monocyclic or polycyclic aromatic or partially saturated aromatic polycyclic, which may optionally contain up to 3 heteroatoms selected from N, S or O. The said monocyclic or polycyclic ring may be unsubstituted or have up to 4 substituents which may be identical or different; m and n independently represents an integer from 0 to 6; A represents O, S or bond; Y is selected from (CH2)p’ (CH2)pB(CH2)q’ (CH2)rB(CH2)pD(CH2)q’ where p, q and r each independently represents an integer from 0 to 6; B and D independently represents S, O, NR4 or a bond, with a proviso that when B and D represents hereto atom p is not zero; R4 represents hydrogen, alkyl, alkenyl, -S(O)2-R8 or -C(O)R8 where R8 is alkyl, alkoxy; R5 and R6 independently represents hydrogen, alkyl, cycloalkyl or alkoxy; R5 and R6 together may form 3-8 membered cyclic ring which may optionally contains one or two hereto atoms selected from O, S or N; R7 represents hydrogen, optionally substituted groups selected form alkyl, cycloalkyl, alkenyl or alkynyl. The present invention also relates to a process for preparation of compounds of formula (I), to pharmaceutical compositions containing compounds of formula (I) and their use in particular as antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic agents.
查看更多

同类化合物

(R)-3-(叔丁基)-4-(2,6-二异丙氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (2S,3R)-3-(叔丁基)-2-(二叔丁基膦基)-4-甲氧基-2,3-二氢苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2R,2''R,3R,3''R)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2-氟-3-异丙氧基苯基)三氟硼酸钾 (+)-6,6'-{[(1R,3R)-1,3-二甲基-1,3基]双(氧)}双[4,8-双(叔丁基)-2,10-二甲氧基-丙二醇 麦角甾烷-6-酮,2,3,22,23-四羟基-,(2a,3a,5a,22S,23S)- 鲁前列醇 顺式6-(对甲氧基苯基)-5-己烯酸 顺式-铂戊脒碘化物 顺式-四氢-2-苯氧基-N,N,N-三甲基-2H-吡喃-3-铵碘化物 顺式-4-甲氧基苯基1-丙烯基醚 顺式-2,4,5-三甲氧基-1-丙烯基苯 顺式-1,3-二甲基-4-苯基-2-氮杂环丁酮 非那西丁杂质7 非那西丁杂质3 非那西丁杂质22 非那西丁杂质18 非那卡因 非布司他杂质37 非布司他杂质30 非布丙醇 雷诺嗪 阿达洛尔 阿达洛尔 阿莫噁酮 阿莫兰特 阿维西利 阿索卡诺 阿米维林 阿立酮 阿曲汀中间体3 阿普洛尔 阿普斯特杂质67 阿普斯特中间体 阿普斯特中间体 阿托西汀EP杂质A 阿托莫西汀杂质24 阿托莫西汀杂质10 阿托莫西汀EP杂质C 阿尼扎芬 阿利克仑中间体3 间苯胺氢氟乙酰氯 间苯二酚二缩水甘油醚 间苯二酚二异丙醇醚 间苯二酚二(2-羟乙基)醚 间苄氧基苯乙醇 间甲苯氧基乙酸肼 间甲苯氧基乙腈 间甲苯异氰酸酯